MX2023014637A - Inhibidor de autotaxina (atx) para el tratamiento del cancer de pancreas. - Google Patents
Inhibidor de autotaxina (atx) para el tratamiento del cancer de pancreas.Info
- Publication number
- MX2023014637A MX2023014637A MX2023014637A MX2023014637A MX2023014637A MX 2023014637 A MX2023014637 A MX 2023014637A MX 2023014637 A MX2023014637 A MX 2023014637A MX 2023014637 A MX2023014637 A MX 2023014637A MX 2023014637 A MX2023014637 A MX 2023014637A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitor
- autotaxin
- atx
- treatment
- pancreatic cancer
- Prior art date
Links
- 102100021977 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Human genes 0.000 title abstract 3
- 108050004000 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 title abstract 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title abstract 2
- 201000002528 pancreatic cancer Diseases 0.000 title abstract 2
- 208000008443 pancreatic carcinoma Diseases 0.000 title abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2108245.8A GB202108245D0 (en) | 2021-06-09 | 2021-06-09 | Methods of treatment |
| PCT/EP2022/065562 WO2022258693A1 (en) | 2021-06-09 | 2022-06-08 | Autotaxin (atx) inhibitor for the treatment of pancreatic cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023014637A true MX2023014637A (es) | 2024-01-31 |
Family
ID=76838834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014637A MX2023014637A (es) | 2021-06-09 | 2022-06-08 | Inhibidor de autotaxina (atx) para el tratamiento del cancer de pancreas. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250057820A1 (https=) |
| EP (1) | EP4351563A1 (https=) |
| JP (1) | JP2024522135A (https=) |
| CN (1) | CN117295496A (https=) |
| AU (1) | AU2022290378A1 (https=) |
| CA (1) | CA3218103A1 (https=) |
| GB (1) | GB202108245D0 (https=) |
| MX (1) | MX2023014637A (https=) |
| WO (1) | WO2022258693A1 (https=) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201502020D0 (en) * | 2015-02-06 | 2015-03-25 | Cancer Rec Tech Ltd | Autotaxin inhibitory compounds |
| JP2024511836A (ja) * | 2021-03-29 | 2024-03-15 | アイオンクチュラ・ソシエテ・アノニム | 膵臓癌の治療のためのｐｉ３ｋ－デルタ阻害剤 |
-
2021
- 2021-06-09 GB GBGB2108245.8A patent/GB202108245D0/en not_active Ceased
-
2022
- 2022-06-08 CN CN202280032188.0A patent/CN117295496A/zh active Pending
- 2022-06-08 MX MX2023014637A patent/MX2023014637A/es unknown
- 2022-06-08 CA CA3218103A patent/CA3218103A1/en active Pending
- 2022-06-08 JP JP2023574275A patent/JP2024522135A/ja active Pending
- 2022-06-08 US US18/567,932 patent/US20250057820A1/en active Pending
- 2022-06-08 EP EP22734239.1A patent/EP4351563A1/en active Pending
- 2022-06-08 WO PCT/EP2022/065562 patent/WO2022258693A1/en not_active Ceased
- 2022-06-08 AU AU2022290378A patent/AU2022290378A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN117295496A (zh) | 2023-12-26 |
| CA3218103A1 (en) | 2022-12-15 |
| GB202108245D0 (en) | 2021-07-21 |
| US20250057820A1 (en) | 2025-02-20 |
| JP2024522135A (ja) | 2024-06-11 |
| EP4351563A1 (en) | 2024-04-17 |
| AU2022290378A1 (en) | 2024-01-04 |
| WO2022258693A1 (en) | 2022-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20240210A1 (ar) | مثبطات kras | |
| ZA202309638B (en) | Pyrimidine-fused cyclic compound, preparation method therefor and use thereof | |
| PH12019501740A1 (en) | Methods for the administration of certain vmat2 inhibitors | |
| WO2021243280A3 (en) | Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9 | |
| PH12021550302A1 (en) | Methods for the administration of certain vmat2 inhibitors | |
| MX2017014338A (es) | Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina. | |
| EP4684836A3 (en) | Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases | |
| AU2003245282A1 (en) | Stent coatings with sustained drug release rate | |
| MXPA05013642A (es) | Composicion de un antagonista de vegf y un agente antiproliferativo y su uso para el tratamiento de cancer. | |
| WO2020191056A8 (en) | Pyridazinones and methods of use thereof | |
| MX2021002349A (es) | Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario. | |
| EP4667493A3 (en) | Lag-3 combination therapy for the treatment of cancer | |
| MX2023011441A (es) | Uso de inhibidores de pi3k-delta para el tratamiento de cancer pancreatico. | |
| MX2023002332A (es) | Terapia con antagonistas del gen 3 de activacion de linfocitos (lag-3) para carcinoma hepatocelular. | |
| WO2022081310A3 (en) | Inhaled pde-v inhibitor drugs | |
| MX2022009197A (es) | Metodos de tratamiento para deficiencia de alfa-1 antitripsina. | |
| MX2010004967A (es) | Uso de inhibidor de cfms para el tratamiento y la prevención del cancer de hueso, así como la perdida osea y el dolor de hueso asociados con el cancer de hueso. | |
| WO2023046060A8 (zh) | 治疗kras突变的癌症患者 | |
| MX2022006566A (es) | Tratamientos conjuntos para tratamiento de cancer de mama. | |
| MX2020011453A (es) | Combinaciones para tratar el cancer. | |
| MX2025009446A (es) | Erdafitinib para administración intravesical para usar en el tratamiento del cáncer de vejiga | |
| MX2023014637A (es) | Inhibidor de autotaxina (atx) para el tratamiento del cancer de pancreas. | |
| WO2022261467A9 (en) | Radioimmunoconjugates and checkpoint inhibitor combination therapy | |
| ZA202206308B (en) | Ezetimibe and curcumin for use in cancer treatment | |
| WO2009047505A3 (en) | Dexanabinol with inhibitors of braf or mek for the treatment of melanoma |